L3VLUP
ProSign in

TVTX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TVTXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TVTX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTVTXJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20205 holders, $183m32 holders, $26.6bn
Q1 20213 holders, $183m31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 20213 holders, $131m40 holders, $24.1bn
Q4 20213 holders, $158m33 holders, $25.2bn
Q1 20225 holders, $150m35 holders, $28.2bn
Q2 20225 holders, $147m33 holders, $26.9bn
Q3 20225 holders, $153m36 holders, $25.4bn
Q4 20225 holders, $157m35 holders, $27.6bn
Q1 20237 holders, $259m42 holders, $24.5bn
Q2 20238 holders, $185m38 holders, $25.0bn
Q3 20232 holders, $22m37 holders, $18.9bn
Q4 20235 holders, $50m31 holders, $19.0bn
Q1 20241 holders, $1.5m32 holders, $19.7bn
Q2 20242 holders, $12m35 holders, $20.4bn
Q3 20244 holders, $75m28 holders, $22.3bn
Q4 20248 holders, $239m37 holders, $20.4bn
Q1 20257 holders, $311m32 holders, $20.5bn
Q2 20256 holders, $207m31 holders, $18.4bn
Q3 20256 holders, $340m32 holders, $23.7bn
Q4 20257 holders, $599m29 holders, $27.8bn
Q1 20264 holders, $400m34 holders, $35.6bn
Q2 20267 holders, $934m33 holders, $39.1bn
TVTX

Travere Therapeutics Inc

Holders
7
Reported value
$934m
Buyers
20
Sellers
15

Breadth +5 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TVTX (4)

ExodusPoint Capital Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP

Only JNJ (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →